# Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg

> **NCT01494727** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 48 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CJ Amlodipine/Valsartan 10/160mg
- **DRUG:** Novartis Exforge 10/160mg

## Key facts

- **NCT ID:** NCT01494727
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2012-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01494727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01494727, "Phase I Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg and Novartis Exforge 10/160mg". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01494727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*